Division of Hematology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Br J Haematol. 2022 Sep;198(6):988-993. doi: 10.1111/bjh.18233. Epub 2022 May 24.
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.
CANDOR 研究比较了卡非佐米联合地塞米松和达雷妥尤单抗（KdD）与卡非佐米联合地塞米松（Kd）治疗复发/难治性多发性骨髓瘤（RRMM）成人患者的安全性/疗效。本 CANDOR 亚组分析根据细胞遗传学风险评估了结局。高危组的总缓解率（KdD 对比 Kd）分别为 81%对比 56%，标准风险组分别为 87%对比 79%。高危组的中位无进展生存期为 11.2 个月对比 7.4 个月（危险比，0.56 [95% CI，0.34，0.93]），标准风险组未达到 16.6 个月（0.56 [95% CI，0.39，0.80]）。这些数据支持 KdD 在 RRMM 治疗中的疗效，包括在细胞遗传学高危的患者中。
